ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NMPA approves oral formulation of Akynzeo in China biospectrumasia
September 25, 2019Riccardo Braglia, Helsinn Group Vice Chairman and CEO?commented: "Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo? that targets two CINV critical pathways in a single dose will help patient
Pharma Sources Insight January 2025
